Aminoglycosides and botulinum toxin: interaction

The question "are you taking any antibiotics?" tends to land in the middle of a busy medical history, and many patients answer no because the course ended "last week." In botulinum toxin procedures, this question deserves more care than routine allows. Some antibiotics, the aminoglycosides, can interfere with neuromuscular transmission and add to the effect of the toxin. This guide explains the mechanism at a review level, what to ask, how to decide and what to record. Timeframes, doses and drug choices are the decision of the licensed practitioner, according to the product's package insert and the rules of their professional board.

What are aminoglycosides and why do they matter here?

Aminoglycosides are a class of antibiotics used for bacterial infections, generally more serious ones. Some examples known by their generic names are gentamicin, amikacin and neomycin. They appear in hospital injections, in topical use (such as ointments and eye drops) and, in some regimens, orally.

The point of interest is pharmacological. These antibiotics can reduce the release of acetylcholine and impair the transmission of the nerve impulse to the muscle fiber, the same territory where the toxin acts. Adding the two effects can intensify muscle weakness.

This does not mean that every patient on an antibiotic cannot receive toxin. It means the information has to be sought out, and the decision made with judgment, never by reflex.

What the interaction can cause

The consequence depends on the toxin dose, the amount of aminoglycoside and individual sensitivity. In general terms:

• Greater than expected weakness in the treated area, and possibly in neighboring muscles.
• Effects at a distance, such as difficulty swallowing, a change in voice and, in severe cases, breathing problems.
• A longer-lasting effect or one that starts faster than usual.

These conditions are uncommon in aesthetic practice, where doses are low. But the practitioner does not get to choose when the patient will be one of the rare cases, so the medical history must be taken with the rigor of a procedure that can have serious consequences. See the overview of unwanted effects in complications with botulinum toxin.

Who else deserves a specific question

The patient does not always remember the antibiotic, but usually remembers the context. Asking in a targeted way helps.

The package insert of the product used lists the medications that deserve attention. When in doubt about a specific drug, the main source is the package insert, complemented by the prescriber's guidance. The knowledge base is in botulinum toxin: fundamentals.

Decision table: from the report to the approach

How to talk to the patient

Avoid creating panic or promising that "it never happens." The goal is to justify the question and the possible wait.

Records, consent and responsibility

What to record at every toxin visit:

• medications in use, with name, dose and end date, when known;
• recent hospitalizations and surgeries;
• the decision made (proceed, postpone, not indicated) and the reason;
• product, units and lot applied, per injectable traceability;
• instructions given to the patient about warning signs.

The toxin's informed consent should cite effects at a distance and the importance of reporting medications. The full record is in patient records and documentation in HOF, and the safety basis in general contraindications in HOF and medical history in HOF.

If you plan to inject outside what the package insert indicates, the rules of off-label use also apply, along with the care to justify and document. The product's package insert, approved by Anvisa (Brazil's health regulatory agency), remains the reference.

Where Harmy comes in

Common mistakes in the toxin medical history

1. Asking only "do you take any medication?" A generic question gets generic answers. Ask about antibiotics, hospitalization and recent surgery.
2. Dismissing topical use. An ointment over a large area or broken skin can have relevant absorption, and the question needs to be asked.
3. Ignoring neuromuscular diseases. Patients with myasthenia or similar conditions require a specific assessment, and the indication may be revised.
4. Relying on the patient's memory. The forgotten drug name may be the most important piece of information. Ask for the prescription or the box.
5. Recording the decision without the reason. "Postponed" is not enough. Note the drug, the date and the reason.

When to talk to the prescriber

When in doubt about the timeframe, dose or need for the antibiotic, contacting the prescribing doctor is usually the best source, since they know the kidney function, the severity of the infection and the length of the regimen. Ask objectively: which drug, for how long, when it ended and whether there is any reason not to receive botulinum toxin for now. Record the answer in the patient record. This kind of dialogue avoids decisions based on assumptions and shows the patient your care for safety.